Skip to main content
Erschienen in: Breast Cancer 1/2014

01.01.2014 | Review Article

Lymph node ratio and breast cancer prognosis: a meta-analysis

verfasst von: Dechun Liu, Yanbin Chen, Miao Deng, Gangqiang Xie, Jianguang Wang, Like Zhang, Qipeng Liu, Pengfei Yuan, Xiaoshan Feng

Erschienen in: Breast Cancer | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Due to the heterogeneity of lymph node examination and the conflicting results existing for the same classification of lymph node ratio (LNR), it is necessary to conduct a meta-analysis to evaluate the prognostic effects of different LNRs on breast cancer. PubMed, EMBASE, and ISI Web of Knowledge were searched to find all published cohort studies that evaluated the prognostic value of different LNRs on breast cancer. The outcomes were overall survival (OS), disease-free survival (DFS), breast cause-special survival (BCCS), mortality, locoregional recurrence (LRR), and distant metastasis. Data was analyzed using comprehensive meta-analysis software version 2.0, and 23 studies were included. The available evidence showed that LNR was a prognostic predictor for breast cancer, especially for clinically node-positive breast cancer, but the available evidence could not judge which cutoff point is the most reliable. Meanwhile, the cutoff values 0.2 and 0.65 could be suitable to predict breast cancer OS, DFS, BCCS, and mortality.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat De Boer M, Van Dijck JAAM, Bult P, et al. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst. 2010;102:410–25.PubMedCrossRef De Boer M, Van Dijck JAAM, Bult P, et al. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst. 2010;102:410–25.PubMedCrossRef
2.
Zurück zum Zitat Vinh-Hung V, Nguyen NP, Cserni G, et al. Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. Future Oncol. 2009;5:1585–603.PubMedCrossRef Vinh-Hung V, Nguyen NP, Cserni G, et al. Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. Future Oncol. 2009;5:1585–603.PubMedCrossRef
3.
Zurück zum Zitat Ahn SH, Kim HJ, Lee JW, et al. Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society. Breast Cancer Res Treat. 2011;130:507–15.PubMedCrossRef Ahn SH, Kim HJ, Lee JW, et al. Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society. Breast Cancer Res Treat. 2011;130:507–15.PubMedCrossRef
4.
Zurück zum Zitat Vinh-Hung V, Verkooijen HM, Fioretta G, et al. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol. 2009;27:1062–8.PubMedCrossRef Vinh-Hung V, Verkooijen HM, Fioretta G, et al. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol. 2009;27:1062–8.PubMedCrossRef
5.
Zurück zum Zitat Woodward WA, Vinh-Hung V, Ueno NT, et al. Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol. 2006;24:2910–6.PubMedCrossRef Woodward WA, Vinh-Hung V, Ueno NT, et al. Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol. 2006;24:2910–6.PubMedCrossRef
6.
Zurück zum Zitat Ibrahim EM, Elkhodary TR, Zekri JM, et al. Prognostic value of lymph node ratio in poor prognosis node-positive breast cancer patients in Saudi Arabia. Asia Pac J Clin Oncol. 2010;6:130–7.PubMedCrossRef Ibrahim EM, Elkhodary TR, Zekri JM, et al. Prognostic value of lymph node ratio in poor prognosis node-positive breast cancer patients in Saudi Arabia. Asia Pac J Clin Oncol. 2010;6:130–7.PubMedCrossRef
7.
Zurück zum Zitat Dings PJM, Elferink MAG, Strobbe LJA, et al. The prognostic value of lymph node ratio in node-posjitive breast cancer: a dutch nationwide population-based study. Ann Surg Oncol 2013: 1-8. Dings PJM, Elferink MAG, Strobbe LJA, et al. The prognostic value of lymph node ratio in node-posjitive breast cancer: a dutch nationwide population-based study. Ann Surg Oncol 2013: 1-8.
8.
Zurück zum Zitat Chagpar AB, Camp RL, Rimm DL. Lymph node ratio should be incorporated into staging for breast cancer. Ann Surg Oncol. 2011;18:S155. Chagpar AB, Camp RL, Rimm DL. Lymph node ratio should be incorporated into staging for breast cancer. Ann Surg Oncol. 2011;18:S155.
9.
Zurück zum Zitat Tendulkar RD, Rehman S, Shukla ME, et al. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1–3 positive lymph nodes treated with modern systemic therapy. Int J Radiat Oncol Biol Phys. 2012;83:e577–81.PubMedCrossRef Tendulkar RD, Rehman S, Shukla ME, et al. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1–3 positive lymph nodes treated with modern systemic therapy. Int J Radiat Oncol Biol Phys. 2012;83:e577–81.PubMedCrossRef
10.
Zurück zum Zitat Saxena N, Hartman M, Yip CH, et al. Does the axillary lymph node ratio have any added prognostic value over pN Staging for south east Asian breast cancer patients? PLoS One. 2012;7(9):e45809.PubMedCentralPubMedCrossRef Saxena N, Hartman M, Yip CH, et al. Does the axillary lymph node ratio have any added prognostic value over pN Staging for south east Asian breast cancer patients? PLoS One. 2012;7(9):e45809.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Huang CJ, Hou MF, Chuang HY, et al. Comparison of clinical outcome of breast cancer patients with T1–2 tumor and one to three positive nodes with or without postmastectomy radiation therapy. Jpn J Clin Oncol. 2012;42:711–20.PubMedCrossRef Huang CJ, Hou MF, Chuang HY, et al. Comparison of clinical outcome of breast cancer patients with T1–2 tumor and one to three positive nodes with or without postmastectomy radiation therapy. Jpn J Clin Oncol. 2012;42:711–20.PubMedCrossRef
12.
Zurück zum Zitat Saxena N, Hartman M, Aziz R, et al. Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. Results from a multicentre study. Eur J Cancer. 2011;47:1186–92.PubMedCrossRef Saxena N, Hartman M, Aziz R, et al. Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. Results from a multicentre study. Eur J Cancer. 2011;47:1186–92.PubMedCrossRef
13.
Zurück zum Zitat Kim JY, Ryu MR, Choi BO, et al. The prognostic significance of the lymph node ratio in axillary lymph node positive breast cancer. J Breast Cancer. 2011;14:204–12.PubMedCentralPubMedCrossRef Kim JY, Ryu MR, Choi BO, et al. The prognostic significance of the lymph node ratio in axillary lymph node positive breast cancer. J Breast Cancer. 2011;14:204–12.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Karihtala P, Winqvist R, Bloigu R, et al. Long-term observational follow-up study of breast cancer diagnosed in women ≤ 40 years old. Breast. 2010;19:456–61.PubMedCrossRef Karihtala P, Winqvist R, Bloigu R, et al. Long-term observational follow-up study of breast cancer diagnosed in women ≤ 40 years old. Breast. 2010;19:456–61.PubMedCrossRef
16.
Zurück zum Zitat Martinez-Ramos D, Escrig-Sos J, Alcalde-Sanchez M, et al. Disease-free survival and prognostic significance of metastatic lymph node ratio in T1–T2 N positive breast cancer patients. A population registry-based study in a European country. World J Surg. 2009;33:1659–64.PubMedCrossRef Martinez-Ramos D, Escrig-Sos J, Alcalde-Sanchez M, et al. Disease-free survival and prognostic significance of metastatic lymph node ratio in T1–T2 N positive breast cancer patients. A population registry-based study in a European country. World J Surg. 2009;33:1659–64.PubMedCrossRef
17.
Zurück zum Zitat Keam B, Im SA, Kim HJ, et al. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2009;116:153–60.PubMedCrossRef Keam B, Im SA, Kim HJ, et al. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2009;116:153–60.PubMedCrossRef
18.
Zurück zum Zitat Hatoum HA, Jamali FR, El-Saghir NS, et al. Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer. Ann Surg Oncol. 2009;16:3388–95.PubMedCrossRef Hatoum HA, Jamali FR, El-Saghir NS, et al. Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer. Ann Surg Oncol. 2009;16:3388–95.PubMedCrossRef
19.
Zurück zum Zitat Duraker N, Caynak ZC, Bati B. Is there any prognostically different subgroup among patients with stage IIIC (any TN3M0) breast carcinoma? Ann Surg Oncol. 2008;15:430–7.PubMedCrossRef Duraker N, Caynak ZC, Bati B. Is there any prognostically different subgroup among patients with stage IIIC (any TN3M0) breast carcinoma? Ann Surg Oncol. 2008;15:430–7.PubMedCrossRef
20.
Zurück zum Zitat Kuru B. Prognostic significance of total number of nodes removed, negative nodes removed, and ratio of positive nodes to removed nodes in node positive breast carcinoma. Eur J Surg Oncol. 2006;32:1082–8.PubMedCrossRef Kuru B. Prognostic significance of total number of nodes removed, negative nodes removed, and ratio of positive nodes to removed nodes in node positive breast carcinoma. Eur J Surg Oncol. 2006;32:1082–8.PubMedCrossRef
21.
Zurück zum Zitat Truong PT, Berthelet E, Lee J, et al. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer. 2005;103:2006–14.PubMedCrossRef Truong PT, Berthelet E, Lee J, et al. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer. 2005;103:2006–14.PubMedCrossRef
22.
Zurück zum Zitat Voordeckers M, Vinh-Hung V, Van de Steene J, et al. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol. 2004;70:225–30.PubMedCrossRef Voordeckers M, Vinh-Hung V, Van de Steene J, et al. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol. 2004;70:225–30.PubMedCrossRef
23.
Zurück zum Zitat van der Wal BC, Butzelaar RM, van der Meij S, et al. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol. 2002;28:481–9.PubMedCrossRef van der Wal BC, Butzelaar RM, van der Meij S, et al. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol. 2002;28:481–9.PubMedCrossRef
24.
Zurück zum Zitat Nieto Y, Nawaz S, Jones RB, et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol. 2002;20:707–18.PubMedCrossRef Nieto Y, Nawaz S, Jones RB, et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol. 2002;20:707–18.PubMedCrossRef
25.
Zurück zum Zitat Schneeweiss A, Goerner R, Hensel MA, et al. Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy. Biol Blood Marrow Transpl. 2001;7:332–42.CrossRef Schneeweiss A, Goerner R, Hensel MA, et al. Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy. Biol Blood Marrow Transpl. 2001;7:332–42.CrossRef
26.
Zurück zum Zitat Nieto Y, Cagnoni PJ, Shpall EJ, et al. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. Clin Cancer Res. 1999;5:3425–31.PubMed Nieto Y, Cagnoni PJ, Shpall EJ, et al. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. Clin Cancer Res. 1999;5:3425–31.PubMed
27.
Zurück zum Zitat Vinh-Hung V, Joseph SA, Coutty N, et al. Age and axillary lymph node ratio in postmenopausal women with T1–T2 node positive breast cancer. Oncologist. 2010;15:1050–62.PubMedCentralPubMedCrossRef Vinh-Hung V, Joseph SA, Coutty N, et al. Age and axillary lymph node ratio in postmenopausal women with T1–T2 node positive breast cancer. Oncologist. 2010;15:1050–62.PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Lale Atahan I, Yildiz F, Ozyigit G, et al. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer. Acta Oncol. 2008;47:232–8.PubMedCrossRef Lale Atahan I, Yildiz F, Ozyigit G, et al. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer. Acta Oncol. 2008;47:232–8.PubMedCrossRef
29.
Zurück zum Zitat Truong PT, Woodward WA, Thames HD, et al. The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1–3 positive nodes: an analysis of prospective data from British Columbia and the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 2007;68:59–65.PubMedCrossRef Truong PT, Woodward WA, Thames HD, et al. The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1–3 positive nodes: an analysis of prospective data from British Columbia and the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 2007;68:59–65.PubMedCrossRef
30.
Zurück zum Zitat Ferrari A, Rovera F, Dionigi P, et al. Sentinel lymph node biopsy as the new standard of care in the surgical treatment for breast cancer. Expert Rev Anticancer Ther. 2006;6:1503–15.PubMedCrossRef Ferrari A, Rovera F, Dionigi P, et al. Sentinel lymph node biopsy as the new standard of care in the surgical treatment for breast cancer. Expert Rev Anticancer Ther. 2006;6:1503–15.PubMedCrossRef
31.
Zurück zum Zitat Baslaim MM, Al Malik OA, Al-Sobhi SS, et al. Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy. Am J Surg. 2002;184:299–301.PubMedCrossRef Baslaim MM, Al Malik OA, Al-Sobhi SS, et al. Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy. Am J Surg. 2002;184:299–301.PubMedCrossRef
32.
Zurück zum Zitat Schaapveld M, Otter R, de Vries EG, et al. Variability in axillary lymph node dissection for breast cancer. J Surg Oncol. 2004;87:4–12.PubMedCrossRef Schaapveld M, Otter R, de Vries EG, et al. Variability in axillary lymph node dissection for breast cancer. J Surg Oncol. 2004;87:4–12.PubMedCrossRef
Metadaten
Titel
Lymph node ratio and breast cancer prognosis: a meta-analysis
verfasst von
Dechun Liu
Yanbin Chen
Miao Deng
Gangqiang Xie
Jianguang Wang
Like Zhang
Qipeng Liu
Pengfei Yuan
Xiaoshan Feng
Publikationsdatum
01.01.2014
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 1/2014
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-013-0497-8

Weitere Artikel der Ausgabe 1/2014

Breast Cancer 1/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.